Brompheniramine

Brompheniramine
Clinical data
Trade names	Bromfed, Dimetapp, Bromfenex, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682545
Routes of; administration	By mouth
ATC code	R06AB01 (WHO) ;
Legal status
Legal status	AU: S4 / S3 / S2; US: Rx-only / OTC;
Pharmacokinetic data
Metabolism	Liver
Elimination half-life	24.9 ± 9.3 hours
Excretion	Kidney
Identifiers
	IUPAC name (R/S)-3-(4-Bromophenyl)-N,N-dimethyl-3-pyridin-2-yl-propan-1-amine;
CAS Number	86-22-6 ;
PubChem CID	6834;
IUPHAR/BPS	7133;
DrugBank	DB00835 ;
ChemSpider	6573 ;
UNII	H57G17P2FN;
KEGG	D07543 ;
ChEBI	CHEBI:3183 ;
ChEMBL	ChEMBL811 ;
CompTox Dashboard (EPA)	DTXSID5022691 ;
ECHA InfoCard	100.001.507
Chemical and physical data
Formula	C16H19BrN2
Molar mass	319.246 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Brc1ccc(cc1)C(c2ncccc2)CCN(C)C;
	InChI InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 ; Key:ZDIGNSYAACHWNL-UHFFFAOYSA-N ;
	(verify)

Brompheniramine, sold under the brand name Dimetapp among others, is a first-generation antihistamine drug of the propylamine (alkylamine) class. It is indicated for the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. Like the other first-generation drugs of its class, it is considered a sedating antihistamine.

It was patented in 1948 and came into medical use in 1955. In 2022, the combination with dextromethorphan and pseudoephedrine was the 265th most commonly prescribed medication in the United States, with more than 1 million prescriptions.